[TED]Joe Lassiter: We need nuclear power to solve climate change

發表於 社會經濟 | 發表迴響

談英川通話後續發展 謝金河:台再追公平正義 恐沒明天

 /整理報導

new6-1

針對日前英川通話一事,謝金河今日特於臉書發文,認為未來10年,台灣夾在中美大國博奕的大局中,恐怕難以維持現狀。(圖/中時資料照)

美國準總統川普與總統蔡英文的一通電話,打破台美自1979年斷交以來,雙方領袖首次直接通話的紀錄,引起各界熱議。對此,財訊傳媒董事長謝金河今(4)日於臉書發文,認為此次熱線,未來必將在美、中、台三方引起波動,擔憂台灣若繼續追求公平正義,可能沒有明天!

針對日前英川通話一事,謝金河今日特於臉書發文,開頭即表示,「未來勢必在美、中、台三方引起很大的漣漪。」他點出未來10年,台灣夾在中美大國博奕的大局中,恐怕難以維持現狀。

繼續閱讀

發表於 政治觀察, 社會經濟 | 發表迴響

GROWING IN OUR ADVERSITY

Like any good father, God wants to see His children grow. And His primary way of growing our faith is through adversity—there simply is no more effective way of deepening our relationship with Him. But we must choose to view adversity as an opportunity, rather than as an obstacle. When we do that, we grow in our Christlikeness. Adversity is a given. Growth is optional.

發表於 社會經濟 | 發表迴響

聖經鳥瞰29 羅馬書(一)(王生台弟兄)

發表於 歷史軼聞, 社會經濟 | 發表迴響

罗辑思维 199 你是巨婴吗?

發表於 政治觀察, 歷史軼聞, 社會經濟 | 發表迴響

[TED]Chris Anderson: How web video powers global innovation

發表於 社會經濟 | 發表迴響

美丽的她是美国原子弹之母,袁世凯之孙媳妇,邓小平密友,美国人怀疑中国原子弹是她的杰作……

2016-12-01 冷眼文摘

new5-1

1945年8月6日和9日,
美国分别在日本的广岛,
和长崎投下了原子弹,
超过30万日本人,
葬身于恐怖的核武器。
随着苏联军队出兵我国东北,
日本天皇于15日宣布无条件投降,
第二次世界大战宣告结束。

这两颗原子弹的成功引爆,
要归功于美国于1942年,
制定的代号为“曼哈顿”的绝密计划,
即陆军部研制原子弹计划,
该工程汇集了一大批,
来自世界各国的顶尖科学家,
这其中,
就有唯一的华人女物理学家
——吴健雄。

繼續閱讀

發表於 歷史軼聞 | 發表迴響

Love To You Taiwan – Lobo

發表於 樂音悠揚 | 發表迴響

數字台灣HD131金融業的一場大革命 謝金河 王可言 胡立民

發表於 政治觀察, 社會經濟 | 發表迴響

50 個傳福音最常遇見的問題與解答

C. Caroline Wang
Professor of Business Practice
School of Business and Management
Hong Kong University of Science and Technology

序  言

在我们探索真理的过程中,一定会有很多提问(questions),这些提问会不会成为我们的问题(problems)呢,就看我们在寻找什么?

繼續閱讀

發表於 佳文共賞 | 發表迴響

11/30 生技產業新聞

發表於 產業訊息 | 發表迴響

《老謝看世界》 2016-11-26 航空市場多事之秋!專訪華航董事長 – 何煖軒

發表於 政治觀察, 社會經濟 | 發表迴響

川普經濟學:貿易保護 減稅 製藥能源金融國防成贏家 智能工廠成顯學(文茜世界財經周報)

發表於 政治觀察, 社會經濟 | 發表迴響

工業4.0 :59%的工作會消失,跟不上就淘汰(文茜世界財經周報)

發表於 政治觀察, 社會經濟 | 發表迴響

最新民調:義憲改公投不會過關 歐洲風暴醞釀中(文茜世界財經周報)

發表於 政治觀察, 社會經濟 | 發表迴響

人工智慧發展 人類將步上天堂或地獄(文茜世界財經周報)

發表於 政治觀察, 社會經濟 | 發表迴響

[TED]Steven Johnson: How music led to the invention of modern computers

發表於 社會經濟 | 發表迴響

National Institute of Health Study: UB-421’s HIV Suppression is Superior to 4 Other Broadly Neutralizing Antibodies

Dr. Tae-Wook Chun and his colleagues in Dr. Anthony Fauci’s laboratory at the National Institute of Allergy and Infectious Diseases, NIH, with the NIH-supported AIDS Clinical Trials Group (ACTG) published their latest clinical data on VRC01 (a broadly neutralizing antibody to HIV, bNAb) in people living with HIV in the New England Journal of Medicine (November 24, 2016). In this publication, United BioPharma (UBP)’s UB-421 (an anti-CD4 antibody, which works by a different mechanism than VRC01) was included in the in vitro evaluation of neutralization capability against the HIV isolated from the trial participants.  The anti CD4 antibody UB-421 was shown to have greater effect in vitro when compared to the traditional anti-HIV antibodies, VRC01 and 3 other bNAbs.

A total of 24 participants were enrolled in two phase I clinical trials (ACTG and NIH), and treated with VRC01 (monotherapy) prior to and following discontinuation of antiretroviral therapy (ART). Viral rebound was observed despite high plasma VRC01 concentration (> 50 µg/mL). The median time to rebound was 4 weeks and 5.6 weeks for the ACTG and NIH trials, respectively, suggesting that VRC01 monotherapy can only temporarily replace ART. The researchers demonstrated the persistence of pre-existing and emergence of resistant HIV to VRC01. The data from in vitro neutralization assays involving 182 replication-competent HIV strains isolated from the study participants before and after VRC01 infusion showed that UB-421 was effective in blocking HIV entry when compared to VRC01 and 3 other bNAbs:3BNC117, 10-1074, and PGT121. Of great interest, UB-421 also effectively blocked those HIV isolates that were resistant to those bNAbs (for details, refer to Fig.4A in main article and Fig. S14 in Supplementary Material of this article). UB-421 is currently being evaluated in clinical trials for HIV treatment and viral suppression by the mechanism of HIV entry inhibition.

Source of Article:

KJ Bar et al. Effect of HIV-specific antibody VRC01 on viral rebound after treatment interruption. New England Journal of Medicine, Nov. 24, 2016, Vol.375 No.21, 2037-2050.

繼續閱讀

發表於 公司新聞, 生醫新知, 社會經濟 | 發表迴響